---
title: "Xolair (omalizumab) in allergic asthma: Indication questions"
description: "Indication questions on Xolair (omalizumab) in allergic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Testing. Questions: What is Xolair approved for in asthma? Can Xolair treat an acute asthma attack? When was Xolair first approved for allergic asthma? What lab test is needed to dose Xolair for asthma? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/xolair--allergic-asthma/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xolair (omalizumab) in allergic asthma: Indication questions

Manufacturer: Genentech, Inc.; Novartis Pharmaceuticals Corporation  
Prescribing information: [Xolair](https://www.gene.com/download/pdf/xolair_prescribing.pdf)

Indication questions that apply to every indication of Xolair are on [Xolair (omalizumab), all indications: Indication](https://www.evicenter.com/medical-information/xolair/indication).

## Indication

<a id="xolair-indication"></a>

### What is Xolair approved for in asthma?

> “XOLAIR<sup>®</sup> (omalizumab) is indicated for:”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=%28omalizumab%29%20is%20indicated%20for%3A)

> “Adults and pediatric patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Adults%20and%20pediatric%20patients%206,inadequately%20controlled%20with%20inhaled%20corticosteroids.)

> “Limitations of Use: XOLAIR is not indicated for the relief of acute bronchospasm or status asthmaticus.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Limitations%20of%20Use%3A%20XOLAIR%20is,acute%20bronchospasm%20or%20status%20asthmaticus.)

<a id="xolair-acute-asthma-attacks"></a>

### Can Xolair treat an acute asthma attack?

> “Acute Asthma Symptoms and Deteriorating Disease: XOLAIR has not been shown to alleviate asthma exacerbations acutely. Do not use XOLAIR to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with XOLAIR.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Acute%20Asthma%20Symptoms%20and%20Deteriorating,initiation%20of%20treatment%20with%20XOLAIR.)

<a id="xolair-approval-date"></a>

### When was Xolair first approved for allergic asthma?

> “*Approved since 2003 for patients with uncontrolled moderate to severe allergic asthma, age 12+.<sup>4,8</sup>”

Source: [XOLAIR: Allergic Asthma Treatment | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma.html#:~:text=%2AApproved%20since%202003%20for%20patients,to%20severe%20allergic%20asthma%2C%20age)

> “Initial U.S. Approval:  2003”

Source: [XOLAIR: Prescribing information, page 1, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=1)

Note: The 2003 approval covered patients 12 years of age and older; the indication now includes patients 6 years of age and older. The captured pages do not state when the pediatric indication was added.

## Testing

<a id="xolair-ige-test-for-dosing"></a>

### What lab test is needed to dose Xolair for asthma?

> “Determine dosage of XOLAIR by serum total IgE level (IU/mL) measured before the start 
> of treatment, and by body weight (kg).”

Source: [XOLAIR: Prescribing information, page 4, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=4)

## Related pages
- [Medical information: Xolair (omalizumab): Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma)
- [Pharmacology](https://www.evicenter.com/medical-information/xolair--allergic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/xolair--allergic-asthma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/xolair--allergic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xolair--allergic-asthma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xolair--allergic-asthma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xolair--allergic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xolair--allergic-asthma/access-and-coverage)
